SIGA

SIGA Technologies Inc. - 10-K Summary (Fiscal Year Ended Dec 31, 2007)

Business Context and Reporting Period

Company: SIGA Technologies, Inc.
Reporting Period: Fiscal year ended December 31, 2007.
Business Model: A biotechnology corporation focused on discovering, developing, and commercializing novel anti-infectives for serious infectious diseases, with a primary emphasis on biological warfare defense agents (Smallpox and Arenaviruses). The company has no commercial products and relies on government grants, contracts, and equity financing to fund operations.

Key Financial Metrics

Revenue Composition: 71% of 2007 revenue was derived from National Institutes of Health (NIH) contracts and grants. The remainder came from U.S. Air Force and U.S. Army contracts.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 7.7% ($560,000) compared to 2006. This was primarily due to the completion of a one-year U.S. Army agreement and a Phase I NIH grant in 2006 that did not recur in 2007.
• Net Loss Improvement: Net loss decreased significantly from $9.9 million in 2006 to $5.6 million in 2007. This improvement was largely driven by a $1.4 million gain in 2007 from the decrease in the fair market value of common stock warrants and rights, compared to a $3.1 million loss in 2006.
• Expense Trends: Selling, General, and Administrative (SG&A) expenses decreased by 20% ($920,000) due to the absence of professional fees related to a potential business transaction that occurred in 2006. Research and Development (R&D) expenses increased by 8.7% ($790,000) due to increased clinical testing and payroll costs.
• Liquidity: Cash balances declined by approximately $3.8 million during the year, reflecting continued operating cash burn despite financing inflows from warrant exercises.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects to incur operating losses for the foreseeable future. The company believes existing cash balances combined with anticipated government grants and contracts will support operations beyond the next twelve months. No commercial products are expected to generate revenue in the short term.
• Key Programs:
  • ST-246 (Smallpox): Lead product candidate. Received Orphan Drug designation. Completed Phase I safety studies in 2007. Estimated cost to complete development is $15 million to $20 million over 24-36 months.
  • ST-294 (Arenaviruses): Lead candidate for hemorrhagic fevers. Supported by NIH grants.
• Legal Contingency: PharmAthene, Inc. filed a lawsuit in December 2006 seeking a license to ST-246 and damages. In January 2008, the Court of Chancery denied SIGA's motion to dismiss, and discovery is proceeding. SIGA intends to defend vigorously.
• Risks:
  • Dependence on government grants and contracts for the majority of revenue.
  • High risk of failure in clinical trials and regulatory approval.
  • Need for additional equity financing to sustain operations.
  • Volatility in stock price and potential dilution from warrant exercises.

Investor Verification Checklist

• Grant Sustainability: Verify the renewal status and funding certainty of the major NIH contracts (specifically the $16.5M contract and $4.8M grant for ST-246) which expire in 2009.
• Legal Exposure: Monitor the status of the PharmAthene litigation regarding the ST-246 license obligation and potential damages.
• Cash Runway: Assess the sufficiency of the $6.8 million cash balance against the projected $15-20 million cost to complete ST-246 development and ongoing operating burn rate.
• Warrant Liability: Review the impact of the fair value accounting for outstanding warrants (classified as liabilities) on future earnings volatility.
• Patent Portfolio: Confirm the status of patent applications and expiration dates for core technologies, noting that some key patents expire as early as 2008.